Use of Cell-SELEX to Generate DNA Aptamers as Molecular Probes of HPV-Associated Cervical Cancer Cells

被引:74
作者
Graham, Jessica C. [1 ]
Zarbl, Helmut [1 ,2 ,3 ]
机构
[1] Univ Med & Dent New Jersey, Sch Med, Dept Environm & Occupat Med, Piscataway, NJ 08854 USA
[2] Canc Inst New Jersey, Div Publ Hlth Sci, Program Carcinogenesis & Chemoprevent, New Brunswick, NJ USA
[3] Univ Med & Dent New Jersey, NIEHS Ctr Environm Exposures & Dis, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA
关键词
IN-VITRO SELECTION; NONTUMORIGENIC REVERTANTS; EXPONENTIAL ENRICHMENT; SYSTEMATIC EVOLUTION; LIGANDS; ANGIOGENESIS; PEGAPTANIB; TOXIN;
D O I
10.1371/journal.pone.0036103
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Disease-specific biomarkers are an important tool for the timely and effective management of pathological conditions, including determination of susceptibility, diagnosis, and monitoring efficacy of preventive or therapeutic strategies. Aptamers, comprising single-stranded or double-stranded DNA or RNA, can serve as biomarkers of disease or biological states. Aptamers can bind to specific epitopes on macromolecules by virtue of their three dimensional structures and, much like antibodies, aptamers can be used to target specific epitopes on the basis of their molecular shape. The Systematic Evolution of Ligands by EXponential enrichment (SELEX) is the approach used to select high affinity aptamers for specific macromolecular targets from among the >10(13) oligomers comprising typical random oligomer libraries. In the present study, we used live cell-based SELEX to identify DNA aptamers which recognize cell surface differences between HPV-transformed cervical carcinoma cancer cells and isogenic, nontumorigenic, revertant cell lines. Methodology/Principal Findings: Whole-cell SELEX methodology was adapted for use with adherent cell lines (which we termed Adherent Cell-SELEX (AC-SELEX)). Using this approach, we identified high affinity aptamers (nanomolar range K-d) to epitopes specific to the cell surface of two nontumorigenic, nontumorigenic revertants derived from the human cervical cancer HeLa cell line, and demonstrated the loss of these epitopes in another human papillomavirus transformed cervical cancer cell line (SiHa). We also performed preliminary investigation of the aptamer epitopes and their binding characteristics. Conclusions/Significance: Using AC-SELEX we have generated several aptamers that have high affinity and specificity to the nontumorigenic, revertant of HPV-transformed cervical cancer cells. These aptamers can be used to identify new biomarkers that are related to carcinogenesis. Panels of aptamers, such as these may be useful in predicting the tumorigenic potential and properties of cancer biopsies and aid in the effective management of pathological conditions (diagnosis, predicted outcome, and treatment options).
引用
收藏
页数:9
相关论文
共 38 条
[1]  
Athanassiou M, 1999, CELL GROWTH DIFFER, V10, P729
[2]  
Boylan MO, 1996, CELL GROWTH DIFFER, V7, P725
[3]  
Centers for Disease Control and Prevention: Division of Cancer Prevention and Control, 2010, HUM PAP HPV ASS CANC
[4]   RETRACTED: Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase (Retracted Article) [J].
Cerchia, L ;
Ducongé, F ;
Pestourie, C ;
Boulay, J ;
Aissouni, Y ;
Gombert, K ;
Tavitian, B ;
de Franciscis, V ;
Libri, D .
PLOS BIOLOGY, 2005, 3 (04) :697-704
[5]   Nucleic acid aptamers in cancer medicine [J].
Cerchia, L ;
Hamm, J ;
Libri, D ;
Tavitian, B ;
de Franciscis, V .
FEBS LETTERS, 2002, 528 (1-3) :12-16
[6]   Targeting cancer cells with nucleic acid aptamers [J].
Cerchia, Laura ;
de Franciscis, Vittorio .
TRENDS IN BIOTECHNOLOGY, 2010, 28 (10) :517-525
[7]   Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States [J].
Chaturvedi, Anil K. ;
Engels, Eric A. ;
Pfeiffer, Ruth M. ;
Hernandez, Brenda Y. ;
Xiao, Weihong ;
Kim, Esther ;
Jiang, Bo ;
Goodman, Marc T. ;
Sibug-Saber, Maria ;
Cozen, Wendy ;
Liu, Lihua ;
Lynch, Charles F. ;
Wentzensen, Nicolas ;
Jordan, Richard C. ;
Altekruse, Sean ;
Anderson, William F. ;
Rosenberg, Philip S. ;
Gillison, Maura L. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4294-4301
[8]   A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema [J].
Cunningham, ET Jr ;
Adamis, AP ;
Altaweel, M ;
Aiello, LP ;
Bressler, NM ;
D'Amico, DJ ;
Goldbaum, M ;
Guyer, DR ;
Katz, B ;
Patel, M ;
Schwartz, SD .
OPHTHALMOLOGY, 2005, 112 (10) :1747-1757
[9]   INVITRO SELECTION OF RNA MOLECULES THAT BIND SPECIFIC LIGANDS [J].
ELLINGTON, AD ;
SZOSTAK, JW .
NATURE, 1990, 346 (6287) :818-822
[10]   Biochemistry - Adaptive recognition by nucleic acid aptamers [J].
Hermann, T ;
Patel, DJ .
SCIENCE, 2000, 287 (5454) :820-825